The effectiveness and safety of the use of ethylmethylhydroxypyridine of succinate in the framework of sequential therapy in patients with chronic brain ischemia

Author:
V.V. Burdakov, D.V. Red

FSBEI in Orenburg State Medical University of the Ministry of Health of Russia, Orenburg, Russia

Place of publication:
NEUROLOGY, NEUROPSYCHIATRY, PSYCHOSOMATICS. 2020;12(1):56–60

Abstract:
The aim of the study was to evaluate the efficacy and safety of Mexidol ^® FORTE 250 in patients with chronic cerebral ischemia (CCI) associated with arterial hypertension (AH) and atherosclerosis. Patients and methods. The study included 20 patients aged 45 to 75 years with CCI associated with AH and atherosclerosis, who received Mexidol ^® intravenously (500 mg once daily) for 14 days, followed by oral administration of Mexidol ^® FORTE 250 at a dose of 250 mg 3 times daily for 60 days (main group). The control group consisted of 14 patients with CCI associated with AH and atherosclerosis, who were prescribed combination therapy for CCI without these drugs. Patients were examined before and after 14 and 60 days of treatment. Subjective complaints, neurological symptoms, and Tinetti Functional Mobility Assessment in Elderly Patients scores; Montreal Cognitive Assessment (MoCA); Hamilton Anxiety Rating Scale (HARS); Multidimensional Fatigue Inventory (MFI-20); and Clinical Global Impression (CGI) were studied dynamically. Results and discussion. It was established that Mexidol® therapy ⁱⁿ patients with CCI against the background of hypertension and atherosclerosis was accompanied by positive dynamics according to the MFI-20 asthenia scale, MoCA cognitive functions, and Tinetti motor coordination. No reliable differences in these indicators were noted in patients of the control group. The combination therapy of chronic cerebral ischemia, including Mexidol ^® and Mexidol ^® FORTE 250 as a sequential therapy, turned out to be more than 2 times more effective than the combination therapy of chronic cerebral ischemia without these drugs, according to the scale data, and up to 10 times more effective according to individual scale parameter values. Conclusion. The results of the study of Mexidol ^® FORTE 250 as part of sequential therapy, used according to the above-mentioned regimen, indicate its clinical efficacy and safety in patients with chronic cerebral ischemia. Key words: chronic cerebral ischemia; cognitive and motor functions; asthenic and anxiety-depressive disorders; Mexidol ^® FORTE 250.